GlassScriptPhysician profile
Alexander Pujol
NPI 1730286691
$4,680.80
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,368 · 2022: $904 · 2023: $1,283 · 2024: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059 · Travel and Lodging: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.09 |
| Travel and Lodging | $349.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,512.01 | 2022-2024 | Vanta Adaptivestim, Intellis Adaptivestim |
| Biohaven Pharmaceuticals, INC. | $1,029.69 | 2021 | |
| Redhill Biopharma INC. | $923.29 | 2021 | |
| Boston Scientific Corporation | $302.60 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $217.07 | 2022-2024 | |
| Stimwave Technologies Incorporated | $122.35 | 2022 | |
| Amgen INC. | $85.92 | 2021-2022 | |
| Depuy Synthes Sales INC. | $51.51 | 2022 | |
| Abbott Laboratories | $50.87 | 2021-2024 | Eterna |
| Ibsa Pharma INC. | $50.30 | 2021-2023 | Tirosint, Licart |
| Pear Therapeutics (US), INC. | $45.97 | 2021 | |
| Forte Bio-Pharma LLC | $43.97 | 2021-2024 | Prolate, Nalocet |
| Nevro Corp. | $33.39 | 2021 | |
| Almatica Pharma LLC | $28.86 | 2021 | |
| Spr Therapeutics, INC | $26.25 | 2023 | Sprint Pns System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $25.72 | 2021 | |
| Tersera Therapeutics LLC | $24.44 | 2021 | |
| Allergan, INC. | $17.98 | 2021 | |
| Grt US Holding, INC. | $17.12 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.84 | 2021 | |
| Biodelivery Sciences International, INC. | $15.80 | 2021 | |
| Amneal Pharmaceuticals LLC | $13.75 | 2023 | Lyvispah |
| Bioventus LLC | $13.00 | 2021 | |
| Pfizer INC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Pujol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.